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Abstract
Background: Two once-daily long-acting muscarinic antagonists (LAMAs) are currently available for the treatment
of chronic obstructive pulmonary disease (COPD) – tiotropium and glycopyrronium. Previous studies have compared
glycopyrronium with open-label tiotropium. In the GLOW5 study, we compare glycopyrronium with blinded
tiotropium.
Methods: In this blinded, double-dummy, parallel group, 12-week study, patients with moderate-to-severe
COPD were randomized 1:1 to glycopyrronium 50 μg once daily or tiotropium 18 μg once daily. The primary
objective was to demonstrate the non-inferiority of glycopyrronium versus blinded tiotropium with respect to
trough forced expiratory volume in 1 second (FEV1) following 12 weeks of treatment (non-inferiority margin: –50 mL).
Secondary objectives were to evaluate glycopyrronium versus tiotropium for other spirometric outcomes,
breathlessness (Transition Dyspnea Index; TDI), health status (St George’s Respiratory Questionnaire; SGRQ),
daily rescue medication use, COPD exacerbations and COPD symptoms over 12 weeks of treatment.
Results: 657 patients were randomized (glycopyrronium: 327; tiotropium: 330); 96% (630 patients) completed
the study. Least squares mean trough FEV1 for both glycopyrronium and tiotropium was 1.405 L at Week 12, meeting
the criterion for non-inferiority (mean treatment difference: 0 mL, 95% CI: –32, 31 mL). Glycopyrronium demonstrated
rapid bronchodilation following first dose on Day 1, with significantly higher FEV1 at all time points from 0–4 h
post-dose versus tiotropium (all p < 0.001). FEV1 area under the curve from 0–4 h (AUC0–4h) post-dose with
glycopyrronium was significantly superior to tiotropium on Day 1 (p < 0.001) and was comparable to tiotropium at
Week 12. Glycopyrronium demonstrated comparable improvements to tiotropium in TDI focal score, SGRQ total score,
rescue medication use and the rate of COPD exacerbations (all p = not significant). Patients on glycopyrronium also
had a significantly lower total COPD symptom score versus patients on tiotropium after 12 weeks (p = 0.035). Adverse
events were reported by a similar percentage of patients receiving glycopyrronium (40.4%) and tiotropium (40.6%).
Conclusion: In patients with moderate-to-severe COPD, 12-week blinded treatment with once-daily glycopyrronium
50 μg or tiotropium 18 μg, provided similar efficacy and safety, with glycopyrronium having a faster onset of action on
Day 1 versus tiotropium.
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Background
Chronic obstructive pulmonary disease (COPD) is char-
acterized by progressive airflow limitation that results in
breathlessness, reduced exercise capacity, chronic cough
and sputum production [1]. Inhaled bronchodilators, in-
cluding long-acting muscarinic antagonists (LAMAs), have
been shown to improve symptoms and health status, while
reducing exacerbation rates, and are the cornerstone of
pharmacological therapy for COPD [1].
Until recently, once-daily (o.d.) tiotropium was the
only LAMA available for patients with COPD. Tiotropium
is a well-known LAMA, is widely prescribed worldwide,
and has been shown to improve lung function, dyspnea,
exercise tolerance, and health status, while reducing acute
exacerbations and potentially mortality, compared with
placebo [1,2]. Two LAMAs, twice-daily (b.i.d.) aclidinium
bromide and o.d. glycopyrronium (NVA237) have been re-
cently approved for the management of COPD [3,4]. Both
are presented in a dry-powder formulation [5,6].
In the Phase III GLycopyrronium bromide in COPD air-
Ways 1, 2 and 3 (GLOW1, GLOW2 and GLOW3) studies
in patients with moderate-to-severe COPD, glycopyrronium
50 μg o.d. demonstrated significantly improved bronchodila-
tion, dyspnea, health status, rescue medication use and ex-
ercise tolerance, and reduced the risk of exacerbations,
compared with placebo [7-9]. In the 52-week GLOW2 study,
glycopyrronium was additionally evaluated against open-
label (OL) tiotropium; the onset of bronchodilation with gly-
copyrronium was more rapid than that of OL tiotropium
18 μg o.d. and improvements in bronchodilation, dyspnea,
health status, exacerbations and rescue medication use
were comparable to those provided by OL tiotropium [9].
As the only once-daily LAMA available for compari-
son versus glycopyrronium, tiotropium is an appropriate
control. However, due to technical difficulties, blinding
tiotropium is challenging and therefore leads to studies
utilizing OL designs [10]. Such studies, however, can intro-
duce study bias in several respects. Patients will know they
are on active treatment and therefore may potentially re-
port treatment effects on symptoms and health out-
comes more positively compared with placebo. In addition,
study staff may introduce bias with regard to decisions af-
fecting continuing study participation, concomitant medi-
cation use and adverse event responses [10]. The present
GLOW5 study is the first study that compares glycopyrro-
nium 50 μg o.d. with blinded tiotropium 18 μg o.d.; the
objective of this study was to investigate the efficacy and
safety of glycopyrronium versus blinded tiotropium in pa-
tients with moderate-to-severe COPD, over 12 weeks.
Methods
Patients
GLOW5 enrolled men and women ≥40 years of age, with
moderate-to-severe stable COPD (Global Initiative for
Chronic Obstructive Lung Disease [GOLD] Stage II or III
according to the 2010 GOLD guidelines) [11], who were
current or ex-smokers with a smoking history of at least
10 pack-years, and a post-bronchodilator forced ex-
piratory volume in 1 second (FEV1) ≥30% and <80%
of predicted and post-bronchodilator FEV1/forced vital
capacity (FVC) <0.70 at screening. Post-bronchodilator re-
fers to 45 minutes after inhalation of 84 μg ipratropium.
The main exclusion criteria were respiratory tract in-
fection within 4 weeks prior to screening; COPD exacer-
bations requiring treatment with antibiotics and/or oral
corticosteroids and/or hospitalization 6 weeks prior to
screening; concomitant pulmonary diseases other than
COPD; clinically significant cardiovascular disease (such
as, but not limited to, unstable ischemic heart disease,
New York Heart Association class III/IV left ventricular
failure, myocardial infarction, arrhythmia [including par-
oxysmal atrial fibrillation]); history of asthma, diabetes,
malignancy of any organ system, long QT syndrome or
QTc >450 ms at screening, symptomatic prostatic hyper-
plasia, bladder-neck obstruction, moderate/severe renal
impairment, urinary retention, narrow-angle glaucoma, a
known history of alpha-1 antitrypsin deficiency; participa-
tion in the active phase of a supervised pulmonary re-
habilitation program; and contraindications for tiotropium
or ipratropium, or history of adverse reactions to inhaled
anticholinergics.
All patients gave written, informed consent to par-
ticipate in the study. The study protocol was reviewed
and approved by Institutional Review Boards and eth-
ics committees at participating centers (Additional file 1:
Table S1).
Study design and treatment
GLOW5 was a multicenter, blinded, double-dummy,
parallel group, 12-week study. After a washout period
(up to 7 days), followed by a 14-day run-in period, pa-
tients were randomized 1:1 to glycopyrronium 50 μg o.d.
(delivered via the Breezhaler® device), tiotropium 18 μg
o.d. (delivered via the HandiHaler® device), or matching
placebos (Figure 1). Study drug was to be taken each
morning between 08:00–11:00. Patients were to discon-
tinue taking long-acting bronchodilator therapy before
starting the run-in period (for at least 7 days for LAMAs
and the long-acting β2-agonist [LABA] indacaterol, and
for 48 h for other LABAs or LABA/inhaled corticoster-
oid [ICS] combinations). Patients on fixed-dose LABA/
ICS combinations were switched to an equivalent dose
of ICS contained in the fixed-dose combination. Patients
were provided with a salbutamol/albuterol (short-acting
β2-agonist; SABA) inhaler to be used as rescue medica-
tion during the study. They were instructed to abstain
from taking rescue medication within 6 h of the start of
each study visit.
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Treatment blinding
A double-dummy design was adopted in the study to
achieve blinding. Following instruction on the correct
use of the two devices, patients completed the inhalation
of glycopyrronium or placebo to glycopyrronium via the
Breezhaler® device followed as closely as they felt com-
fortable to do so by the inhalation of tiotropium or placebo
to tiotropium via the HandiHaler® device, depending on
their randomized treatment schedule. Study sites were
instructed to ensure that glycopyrronium and placebo to
glycopyrronium were only administered via the Breezhaler®
device and that tiotropium and placebo to tiotropium were
only administered via the HandiHaler® device. Addition-
ally, blinding was achieved by specifying that the study
medications be dispensed by a third party not involved in
other aspects of the study, and by the use of study drugs
that were similar in appearance, with the same schedule of
administration.
An automated, interactive, voice-response technology
was used to assign randomization numbers to patients
who met the study criteria. Randomization numbers were
used to link patients to treatment groups, and these were
not communicated to the caller. Randomization data were
kept strictly confidential until the time of unblinding, and
were not accessible by anyone involved in the conduct of
the study.
Efficacy assessments
The primary efficacy objective of the study was to dem-
onstrate the non-inferiority of glycopyrronium versus
tiotropium for the parameter trough FEV1 (defined as
the mean of the 23 h 15 min and the 23 h 45 min post-
dose values), following 12 weeks of treatment. A key sec-
ondary objective was to demonstrate the superiority of
glycopyrronium versus tiotropium on trough FEV1 after
12 weeks of treatment, if the primary objective of non-
inferiority was demonstrated. Other secondary objectives
were to evaluate the effect of glycopyrronium versus
tiotropium on spirometric outcomes (FVC, peak FEV1,
FEV1 area under the curve from 0–4 h [FEV1 AUC0–4h],
inspiratory capacity [IC]), and on breathlessness measured
using Transition Dyspnea Index (TDI) focal score, health
status according to the St George’s Respiratory Question-
naire (SGRQ) total score, daily rescue medication use,
COPD exacerbations and COPD symptoms over 12 weeks
of treatment.
Pulmonary function assessments were performed
using centralized spirometry. All spirometry assessments
were reviewed centrally to ensure the maneuvers met
the standards for repeatability and acceptability. The
spirometer was customized and programmed according
to the requirements of the study protocol in accordance
with American Thoracic Society/European Respiratory
Society standards [12], including predicted reference values.
In order to reduce the variability of observations, the same
equipment was used for all measurements during the study.
Whenever possible, the same staff member coached and
evaluated a patient at each visit. In addition, the spirometer
was calibrated daily before measurements were made.
Spirometric measurements were taken prior to run-in to
determine eligibility and to record post-bronchodilator FEV1
45 minutes after inhalation of up to 84 μg ipratropium.
Thereafter, spirometry was performed at randomization
(Day 1) and Weeks 4 and 12. FEV1 and FVC were re-
corded at all clinic visits at the following time points rela-
tive to the morning dose: 45 and 15 min pre-dose, and 5,
15 and 30 min, 1 h, 23 h 15 min and 23 h 45 min post-
dose on Day 1 and Weeks 4 and 12, and additionally at
2 h, 3 h and 4 h on Day 1 and Week 12. IC was also re-
corded at each clinic visit at 20 min pre-dose, 25 min, 2 h,
4 h and 24 h at Day 1 and Week 12.
Investigator-administered baseline dyspnea index
(BDI) was assessed at Day 1, TDI at Weeks 4 and 12,
and self-administered SGRQ was assessed at Day 1 and
Week 12. All patients were provided with an electronic
diary to record morning and evening symptoms twice
daily. Patients recorded cough, wheezing, shortness of
breath, sputum volume and color, night time awakenings
and impact on daily activities, assigning a rating of 0 to
3 for each (0 being the best and 3 being the worst); the
Randomization






Tiotropium 18 μg o.d.
Screening/run-in
Day -14 to Day -1
Glycopyrronium 50 μg o.d.
Visit 1 Visit 2 Visit 3 (Day 1) to Visit 8 (Day 85) Visit 8
Blinded treatment period (12 weeks)
Figure 1 GLOW5 study design.
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sum of these gave the total symptom scores (further de-
tails are included in Additional file 1: Table S2). Patients
also recorded the use of rescue medication in their diary.
Patient daily diaries were reviewed at Day 1 and Weeks
4 and 12 and features of COPD exacerbation and change
in concomitant medication usage from baseline were
noted.
COPD exacerbations were defined as worsening of
two or more major symptoms (dyspnea, sputum vol-
ume or sputum purulence) for at least 2 consecutive
days or worsening of any one major symptom to-
gether with any minor symptom (colds, fever without
other cause, increased cough, increased wheeze or
sore throat) for at least 2 consecutive days. Exacerba-
tions were considered to be of moderate severity if
they required treatment with systemic corticosteroids,
antibiotics or both, and were considered severe if they
also required hospitalization.
Safety assessments
Safety was assessed by recording all treatment-emergent
adverse events (AEs) and serious AEs (SAEs), monitoring
vital signs and performing laboratory analyses (hematology,
clinical chemistry and urinalysis). An AE was defined as
the appearance or worsening of any undesirable sign,
symptom, or medical condition occurring after starting the
study drug, even if the event was not considered to be re-
lated to study drug. AEs were coded using the Medical
Dictionary of Regulatory Activities (MedDRA) and sum-
marized by primary system organ class, preferred term,
maximum severity and relationship to study drug. An in-
dependent adjudication committee classified the reported
serious cardio- and cerebro-vascular (CCV) events.
Statistical analysis
Three populations were defined for the purpose of ana-
lysis. The full analysis set (FAS) included all randomized
patients who received at least one dose of the study drug
and was analyzed according to the allocated treatment
group. The per-protocol set (PPS) included patients in
the FAS who did not have major protocol deviations;
patients were analyzed according to the treatment they
were randomized to. Patients who did not take ran-
domized treatment as per protocol in the 14 days
prior to the trough assessment at Week 12 were ex-
cluded from the PPS. The safety set consisted of all
patients who received at least one dose of study drug;
patients were analyzed according to the treatment
they received.
The primary analysis was performed in the PPS with im-
putation with last observation carried forward (LOCF),
using a mixed model which contained treatment as a fixed
effect, with the baseline measurement of FEV1 and FEV1
prior to and post inhalation of short-acting bronchodilator
as covariates. The model also included smoking status
at baseline (current/ex-smoker) and baseline ICS use
(yes/no) and region as fixed effects and center nested
within region as a random effect. The non-inferiority of
glycopyrronium to tiotropium was claimed if the lower
bound of the two-sided 95% CI for the treatment differ-
ence was greater than −50 mL.
If the primary objective of non-inferiority was met,
then the superiority of glycopyrronium for trough FEV1
(imputed with LOCF) after 12 weeks of treatment was
evaluated in the FAS using the same mixed model as
specified for the primary analysis. Superiority could be
demonstrated if the treatment difference in the FAS was
statistically significant at the 5% level (two-sided) and the
corresponding 95% CI lay entirely to the right (higher
than) of 0 mL. Other secondary variables were analyzed in
the PPS using the same mixed model as specified for the
primary analysis, with the respective baseline values re-
placing baseline FEV1 as covariates. For each analysis, the
estimated adjusted treatment difference for glycopyrro-
nium minus tiotropium is displayed along with the associ-
ated 95% CI.
The analysis of rate of moderate or severe COPD exac-
erbations was based on a generalized linear model, assum-
ing a negative binomial distribution. The model included
treatment, smoking status at baseline, and baseline ICS
use and region as fixed effects, with baseline total symp-
tom score, COPD exacerbation history (the number of
COPD exacerbations in the year before screening) and
FEV1 prior to and post inhalation of short-acting broncho-
dilator as covariates. Log length of time in the study was
included as an offset. All safety endpoints were summa-
rized for the safety set.
Sample size calculation
The non-inferiority margin for this study was specified
as 50 mL. Based on the assumption that an improve-
ment in FEV1 of approximately 100 mL is likely to be
clinically relevant [13], a non-inferiority margin of 50%
of this value i.e. 50 mL was considered appropriate. A
total of 558 evaluable patients (279 per treatment group)
would achieve a power of no less than 90% based on the
following assumptions: a one-sided non-inferiority test
comparing glycopyrronium to tiotropium with respect to
mean trough FEV1 after 12 weeks of treatment at a sig-
nificance level of 2.5%; a treatment difference of 0 mL in
mean trough FEV1 after 12 weeks of treatment; a stand-
ard deviation of 200 mL; a non-inferiority margin (max-
imum allowable difference between the two treatment
groups) of 50 mL in favor of tiotropium.
It was calculated that approximately 660 patients (330
per treatment group) would need to be randomized to
make up for the loss of approximately 15% of patients
due to major protocol deviations and drop-outs.
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Results
Patient disposition and baseline characteristics
A total of 980 patients were screened, 657 patients were ran-
domized (glycopyrronium: 327; tiotropium: 330; Figure 2);
96% (630 patients) completed the study. The percentage
of patients who discontinued was similar in both groups.
The two most common reasons for discontinuing treat-
ment were withdrawal of consent and AEs.
Baseline characteristics were similar between the treat-
ment groups (Table 1). Mean age was 63.5 years, 73.8%
of the patients were male, the majority were Caucasian
(69.6%), and approximately one-half were ex-smokers.
Most patients had moderate (58.4%) or severe (41.4%)
COPD; one patient had mild COPD. The mean duration
of COPD was 6.3 years. Approximately 23.6% of the pa-
tients had a documented history of exacerbations in the
previous year. Mean post-bronchodilator FEV1 was 53.5%
predicted and mean post-bronchodilator FEV1/FVC ratio
was 47.3%.
Spirometry
The least squares mean (LSM) trough FEV1 for both gly-
copyrronium and tiotropium was 1.405 L in the PPS
after 12 weeks of treatment; the lower bound of the
two-sided 95% CI for the treatment difference was
higher than −50 mL, thus meeting the criterion for non-
inferiority (LSM treatment difference: 0 mL, 95% CI: –32,
31 mL; one-sided p < 0.001; Table 2). Since the non-
inferiority criterion was met, the superiority of glycopyrro-
nium to tiotropium was tested for trough FEV1 after 12
weeks in the FAS, but no statistically significant difference
was observed between the two treatment groups (mean
difference 4 mL; p = 0.780; Table 2). The corresponding
mean changes from baseline in trough FEV1 at Week 12
was 103 mL for glycopyrronium and 99 mL for tiotropium.
Following first dose on Day 1, significant differences in
FEV1 were observed in favor of glycopyrronium, with
LSM differences of 51 mL at 5 min and 63 mL at 15 min
post-dose versus tiotropium (both p < 0.001; Table 2). Peak
FEV1 and FEV1 AUC0–4h post-dose in the glycopyrronium
treatment group were significantly superior to the tiotro-
pium group on Day 1 (both p < 0.001). FEV1 at all time
points from 0–4 h were also significantly higher with gly-
copyrronium than with tiotropium on Day 1 (all p < 0.001;
Figure 3A). FVC at Day 1 followed a similar pattern and
was significantly higher with glycopyrronium than with
tiotropium at post-dose time points of 5 min (LSM differ-
ence 51 mL; p = 0.008), 15 min (LSM difference 50 mL;
p = 0.020) and 30 min (LSM difference 45 mL; p = 0.046;
Table 2). On Day 1, IC was also significantly higher with
glycopyrronium versus tiotropium at 30 min (p < 0.001)
and 2 h (p < 0.001) post-dose.
At Week 12, peak FEV1, FEV1 at all time points from 0–
4 h and at 24 h (Figure 3B), and FEV1 AUC0–4h (Figure 4)
was comparable between glycopyrronium and tiotropium
(all p = not significant [NS]). IC at 24 h post-dose at Week
12 was similar in the two treatment groups; change from
baseline at all time points measured on Day 1 and Week
12 are presented in Table 3.
Symptoms, health status, exacerbations and diary card
data
At Week 12, a comparable improvement was demon-
strated by glycopyrronium and tiotropium in TDI focal
score, with a non-significant LSM treatment difference










Adverse events 7 (2.1)
Subject withdrew consent 3 (0.9) 
2 (0.6)








Abnormal test procedure result
Discontinued 14 (4.2)
Adverse events 5 (1.5)
Subject withdrew consent 4 (1.2)
0
Inability to use device 0
1 (0.3)
Lost to follow-up 1 (0.3)
Administrative problems 2 (0.6)
Protocol deviation 1 (0.3)
316 (95.8)COMPLETED
Abnormal test procedure result
Unsatisfactory therapuetic effect
Figure 2 Patient disposition, n (%).
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at Week 12 were 2 (2.90) points and 2.3 (3.0) points with
glycopyrronium and tiotropium, respectively. A similar
proportion of patients experienced a clinically mean-
ingful improvement in TDI focal score (≥1 point) in both
treatment groups (58.6%; odds ratio [OR] 1.06; p = 0.753)
at Week 12 [14].
SGRQ total score at Week 12 was comparable between
glycopyrronium and tiotropium, with a non-significant
LSM treatment difference (0.65 points; p = 0.488; Table 2).
Mean changes (improvements) from baseline were −5.60
and −7.25 with glycopyrronium and tiotropium, respect-
ively. A comparable proportion of patients had a clinically
meaningful improvement in the SGRQ total score (≥4
point reduction) at Week 12 in the glycopyrronium and
tiotropium groups (55.2% and 54%, respectively; OR 1.11;
p = 0.575) [15].
The number of patients who experienced a moderate
or severe COPD exacerbation was small in both treat-
ment groups; glycopyrronium (29 patients, 9.7%) and tio-
tropium (22 patients, 7.5%). Exacerbation rates also were
low and similar in the subjects receiving glycopyrro-
nium and tiotropium (0.38 exacerbations/year versus 0.35
exacerbations/year, respectively; rate ratio 1.10, 95% CI:
0.62, 1.93; p = 0.754). Other exacerbation-related endpoints
are presented in the additional file 1: Figure S1.
The mean daily total COPD symptom score was statis-
tically significantly lower with glycopyrronium compared
with tiotropium, with a treatment difference of −0.3
(95% CI: –0.5, 0.0, p = 0.035; Table 2). Rescue medication
use in the two treatment groups was comparable, with
non-significant differences between the two treatment
groups (Table 2).
Safety
The overall incidence of AEs was similar between the
two treatment groups (glycopyrronium 40.4%, tiotro-
pium 40.6%; Table 4).The most frequently reported AE
was COPD worsening, seen with a higher frequency in
the tiotropium group (17.6%) compared with glycopyrro-
nium (15.3%; Table 4). Of the other most frequently oc-
curring AEs (at least three patients in either treatment
group), only nasopharyngitis, headache, upper respira-
tory tract infection, and urinary tract infection occurred
more frequently in the glycopyrronium group versus the
tiotropium group (Table 4). AEs leading to discontinu-
ation occurred in a comparable number of patients in
both groups (Table 4).
SAEs occurred with a similar frequency in the glycopyr-
ronium (3.4%) and tiotropium (3.9%) treatment groups. In-
fections and infestations were the most frequent SAEs;
COPD worsening occurred more frequently in the tiotro-
pium group (1.8%) than in the glycopyrronium group
(0.9%). The proportion of patients with newly occurring or
worsening clinically notable QTcF values was slightly
higher with tiotropium (5.8%) compared with glycopyrro-
nium (4.0%). Two patients in the glycopyrronium group
had QTcF values >480 msec; none in the tiotropium group.
The percentage of patients with an increase in QTcF from
baseline of 30−60 msec were similar between the treat-
ment groups (glycopyrronium 3.4%; tiotropium 3%). No
patient had an increase from baseline in QTcF >60 msec.
The percentage of patients with cardio- and cerebro-
vascular SAEs was similar between the two treatment
groups (0.6%; Table 5). Two patients in the tiotropium
group (0.6%; non-fatal stroke) and none in the glycopyr-
ronium group had a major adverse cardiovascular event.








Mean (SD) age, years 63.2 (7.9) 63.7 (8.0)
Male, n (%) 237 (72.5) 248 (75.2)
Ethnicity, n (%)
Caucasian 225 (68.8) 232 (70.3)
Black 0 0
Asian 95 (29.1) 91 (27.6)
Native American 6 (1.8) 7 (2.1)
Other 1 (0.3) 0
Severity of COPD (GOLD 2010), n (%)
Mild 0 1 (0.3)
Moderate 191 (58.4) 193 (58.5)
Severe 136 (41.6) 136 (41.2)
Mean (SD) duration of COPD, years 6.5 (5.1) 6.2 (5.1)
Baseline COPD exacerbation history*, n (%)
0 exacerbations 255 (78.0) 247 (74.8)
1 exacerbation 52 (15.9) 61 (18.5)
≥2 exacerbations 20 (6.1) 22 (6.7)
ICS use at baseline, n (%) 163 (49.8) 174 (52.7)
Smoking history, n (%)
Ex-smoker 179 (54.7) 182 (55.2)
Current smoker 148 (45.3) 148 (44.8)
Mean (SD) duration of smoking,
pack-years
39.6 (20.4) 40.2 (21.5)
Mean (SD) FEV1 post-bronchodilator, L 1.5 (0.5) 1.5 (0.5)
Mean (SD) post-bronchodilator
FEV1% predicted
53.2 (13.1) 53.9 (12.7)
Mean (SD) post-bronchodilator FEV1
reversibility, %
17.9 (13.5) 17.6 (13.6)
Mean (SD) post-bronchodilator
FEV1/FVC, %
47.4 (10.7) 47.2 (10.5)
Pack-years = total years of smoking multiplied by cigarette packs smoked
per day; *In the year prior to screening; FEV1 = forced expiratory volume in 1
second; FVC = forced vital capacity; SD = standard deviation; o.d. = once-daily.
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There were no new onset atrial flutter events in either
treatment group. One patient in the glycopyrronium
group and none in the tiotropium group had a new-
onset atrial fibrillation event. No deaths were reported
in the study.
Discussion
Glycopyrronium, a once-daily LAMA in development, has
undergone an extensive clinical development programme;
results from three Phase III studies (GLOW1–3) have
demonstrated that once-daily glycopyrronium 50 μg sig-
nificantly improves lung function, dyspnea, health status,
rescue medication use and exercise tolerance, and reduces
the risk of exacerbations, versus placebo, with an accept-
able safety profile [7-9].
Tiotropium is a key comparator in the evaluation of
new bronchodilators; however, there are some challenges
in using tiotropium as a control [10]. Since tiotropium
cannot be easily blinded, several studies have used OL
tiotropium as a control [16-19]. The GLOW2 study also
evaluated glycopyrronium versus OL tiotropium [9]. Al-
though GLOW2 was not powered to show statistical super-
iority of glycopyrronium over tiotropium, glycopyrronium
was found to be comparable to tiotropium for all end-
points assessed. The impact of bias is a potential issue
in an OL design, but it was minimized in the GLOW2
study by the use of objective spirometric endpoints.
The purpose of the GLOW5 study was to allow a blinded
comparison of the efficacy and safety of glycopyrro-
nium to tiotropium in patients with moderate-to-severe
COPD.
In the GLOW5 study, once-daily glycopyrronium
demonstrated non-inferiority to once-daily blinded tio-
tropium in trough FEV1 at Week 12 in patients with
moderate-to-severe COPD. In the daily symptom diaries,
the total COPD symptom score was significantly lower
in the glycopyrronium treatment group versus tiotro-
pium (p = 0.035). Glycopyrronium and tiotropium dem-
onstrated comparable exacerbation rates of 0.38 per
year and 0.35 per year, respectively; this finding must
Table 2 Differences between treatment for primary and secondary efficacy outcomes (PPS)
Variable LSM (95% CI) treatment difference glycopyrronium versus tiotropium p-value
Day 1
FEV1 5 min post-dose, L 0.051 (0.036, 0.066) <0.001
FEV1 15 min post-dose, L 0.063 (0.046, 0.079) <0.001
FVC 5 min post-dose, L 0.051 (0.013, 0.089) 0.008
FVC 15 min post-dose, L 0.050 (0.008, 0.092) 0.020
FVC 30 min post-dose, L 0.045 (0.001, 0.089) 0.046
Peak FEV1 (0–4 h), L 0.055 (0.034, 0.075) <0.001
IC 30 min post-dose, L 0.078 (0.033, 0.123) <0.001
IC 2 h post-dose, L 0.098 (0.045, 0.152) <0.001
FEV1 AUC0–4h, L 0.058 (0.040, 0.076) <0.001
Week 12
Trough FEV1 (non inferiority; PPS; Primary objective)
†, L 0 (−0.032, 0.031) <0.001*
Trough FEV1 (superiority; FAS)
†, L 0.004 (−0.025, 0.034) 0.780
FEV1 AUC0–4h, L 0.023 (−0.006, 0.053) 0.120
Peak FEV1 (0–4 h), L 0.025 (−0.005, 0.055) 0.107
IC 24 h post-dose, L −0.034 (−0.101, 0.033) 0.318
TDI focal score −0.188 (−0.614, 0.237) 0.385
SGRQ total score 0.65 (−1.19, 2.50) 0.488
Over 12 weeks
Rescue medication use
Change from baseline in mean daily number of puffs 0 (−0.3, 0.3) 0.852
Percentage of days with no rescue medication use −1.5 (−6.2, 3.2) 0.528
Change from baseline in mean daily total symptom score¶ −0.3 (−0.5, 0.0) 0.035
Results of analysis in the per protocol set, unless otherwise stated; *One-sided p-value for the test of non-inferiority presented; †Imputed with last observation
carried forward; ¶Scored from 0–3 for both morning and evening symptoms (0 = lowest, 3 = highest; with the possible range of 0–18 for the daily score);
AUC = area under the curve; CI = confidence interval; FAS = full analysis set; FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; IC = inspiratory
capacity; LSM = least squares mean; PPS = per-protocol set; TDI = Transition Dyspnea Index; SGRQ = St George’s Respiratory Questionnaire.





































Figure 3 FEV1 from 0 to 4 h and at 24 h on a) Day 1 and at b) Week 12 (PPS). Data are LSM ± standard error; FEV1 = forced expiratory




















1.52 Δ = 0.058* Δ = 0.023
Day 1            n=298     n=292        n=290        n=282
       1.47       1.493       1.438       1.496
Week 12
Glycopyrronium Tiotropium
Figure 4 FEV1 AUC0–4h treatment differences for glycopyrronium versus tiotropium on Day 1 and at Week 12 (PPS). Data are
LSM ± standard error; *p < 0.001; AUC = area under the curve; FEV1 = forced expiratory volume in 1 second; PPS = per-protocol set.
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be interpreted in the context of this being a 12-week
study and that longer duration trials would normally
be required for assessment of drug efficacy on ex-
acerbation rates. Both glycopyrronium and tiotropium
also similarly improved breathlessness and health sta-
tus, and reduced rescue medication use; this is con-
sistent with the results seen in the GLOW2 study
[9]. Therefore, the closely similar effect of both treat-
ments on lung function and clinical outcomes indi-
cates that both treatments were comparable and similarly
potent.
Similar to the results demonstrated in the GLOW2
study [9], in the current study, glycopyrronium provided
rapid bronchodilation following first dose on Day 1, with
significantly higher FEV1 at all time points from 0–4 h
versus tiotropium (p < 0.001). A rapid onset of broncho-
dilation is a desirable feature in any COPD therapy.
For patients with COPD, symptoms such as dyspnea
and activity limitation are most challenging in the
morning and reflect the greater morning burden of
COPD [20,21]. The rapid onset of bronchodilation with
glycopyrronium administered in the morning can be
expected to have a positive impact on the morning
routines and daily life of patients with COPD. Add-
itionally, a faster onset of action is desirable, as long-
term adherence to therapy may be lower for medications
that do not have an immediate or direct effect on
COPD symptoms [22]. Rapid onset of effect may lead
to better long-term compliance to therapy which in
turn has been shown to correlate with better treatment
outcomes [23].
Both glycopyrronium and tiotropium had acceptable
safety and tolerability profiles, with a comparable overall
incidence of AEs between both treatment groups. Com-
parable safety of glycopyrronium and tiotropium was
also observed in the GLOW2 study [9].
Table 3 Change from baseline and treatment differences
(glycopyrronium vs tiotropium) in IC at all time points












25 min 0.078 (0.033,0.123)* 0.242 (0.252) 0.166 (0.236)
2 h 0.098 (0.045,0.152)* 0.298 (0.304) 0.197 (0.268)
4 h 0.035 (−0.021,0.090) 0.234 (0.284) 0.198 (0.307)
24 h 0.004 (−0.050,0.057) 0.117 (0.293) 0.111 (0.281)
Week 12
−20 min −0.029 (−0.097,0.038) 0.087 (0.369) 0.099 (0.355)
25 min 0.012 (−0.054,0.079) 0.211 (0.365) 0.187 (0.345)
2 h 0.055 (−0.014,0.124) 0.266 (0.368) 0.207 (0.385)
4 h 0.037 (−0.033,0.107) 0.233 (0.371) 0.186 (0.367)
24 h −0.034 (−0.101,0.033) 0.126 (0.357) 0.148 (0.360)
IC = inspiratory capacity; SD = standard deviation; LSM = least squares mean;
CI = confidence interval; *p < 0.001. There were no other statistically significant
differences at any other time point measured.
Table 4 Most frequent AEs (at least three patients in
either treatment group) and discontinuations due to
AEs (safety set), n (%)
Preferred term Glycopyrronium
50 μg o.d.
(N = 327) n (%)
Tiotropium
18 μg o.d.
(N = 330) n (%)
Any AE 132 (40.4) 134 (40.6)
COPD worsening 50 (15.3) 58 (17.6)
Nasopharyngitis 14 (4.3) 8 (2.4)
Headache 12 (3.7) 7 (2.1)
Bacterial upper respiratory
tract infection
10 (3.1) 11 (3.3)
Upper respiratory tract
infection
9 (2.8) 5 (1.5)
Cough 5 (1.5) 5 (1.5)
Viral upper respiratory tract
infection
5 (1.5) 6 (1.8)
Urinary tract infection 4 (1.2) 1 (0.3)
Lower respiratory tract
infection
3 (0.9) 3 (0.9)
Influenza 2 (0.6) 4 (1.2)
Non-cardiac chest pain 2 (0.6) 3 (0.9)
Pneumonia 2 (0.6) 3 (0.9)
Arthralgia 1 (0.3) 5 (1.5)
Dry mouth 1 ( 0.3) 5 (1.5)
Odema peripheral 1 ( 0.3) 5 (1.5)
Blood glucose increased 0 3 (0.9)
Gastritis 0 3 (0.9)
Renal failure acute 0 3 (0.9)
Sinusitis 0 3 (0.9)
Discontinuation due to AE(s) 7 (2.1) 5 (1.5)
AE = adverse event; o.d. = once daily.
Table 5 CCV SAEs, n (%) (safety set)
Glycopyrronium
50 μg o.d.
(N = 327) n (%)
Tiotropium
18 μg o.d.
(N = 330) n (%)
Patients with any serious CCV event 2 (0.6) 2 (0.6)
MACE 0 2 (0.6)




CCV = cardio- and cerebro-vascular; MACE =major cardiovascular adverse
event; o.d. = once daily; SAE = serious adverse event; *Non-cardiac chest pain
syndrome (n = 1), cardiac failure (n = 1).
Chapman et al. BMC Pulmonary Medicine 2014, 14:4 Page 9 of 11
http://www.biomedcentral.com/1471-2466/14/4
Conclusion
The results from the 12-week GLOW5 study demonstrate
that in patients with moderate-to-severe COPD, glycopyr-
ronium 50 μg once daily provided similar efficacy and
safety to tiotropium 18 μg once daily, with glycopyrro-
nium providing a faster onset of action on Day 1 com-
pared with tiotropium.
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